Duality of Interest. N.S. has consulted for and/or received speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, and Roche and has received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche outside the submitted work. G.F. reports research grants paid to her institution from the Spanish Health Institute Carlos III; reports payment of honoraria for lectures from Novo Nordisk as a member of the OPEN Spain Initiative; reports payment or honoraria for participation on advisory boards of AstraZeneca, Eli Lilly and Company, Marabou Foundation, Novo Nordisk, and Regeneron; and reports acting as a volunteer cochair of the scientific advisory board of the European Association for the Study of Obesity. F.A. received support from Eli Lilly and Company paid to the Foundation APHP Pour la Recherche for his participation on boards. L.-E.G.-P., D.C., A.S., F.H., G.G., and I.B. are employees and shareholders of Eli Lilly and Company. No other potential conflicts of interest relevant to this article were reported.